期刊
WORLD JOURNAL OF CLINICAL CASES
卷 7, 期 14, 页码 1753-1763出版社
BAISHIDENG PUBLISHING GROUP INC
DOI: 10.12998/wjcc.v7.i14.1753
关键词
Uterine sarcoma; Uterine leiomyosarcoma; Endometrial stromal sarcoma; Adenosarcoma; Adjuvant therapy; Chemotherapy; Radiotherapy
Uterine sarcomas (US) are rare mesenchymal tumours accounting approximately for 3%-7% of all uterine cancers. Histologically, US are classified into mesenchymal tumours or mixed epithelial and mesenchymal tumours. The group of mesenchymal tumours indudes uterine leiomyosarcoma (uLMS, 65% of cases), endometrial stromal sarcoma (ESS, 21%) - traditionally divided into low grade (LG-ESS) and high grade-undifferentiated uterine sarcoma (5%) and other rare subtypes such as alveolar or embryonal rhabdomyosarcoma. Despite the fact that several drugs demonstrated clinical activity in advanced or metastatic settings, the role of postoperative therapy in US remains controversial. In this review, we have summarised the current state of the art, including the chief trials on adjuvant treatment modalities in US, especially focusing on uLMS, LG-ESS and other rare histotypes.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据